Sanofi is a multinational pharmaceutical company headquartered in Paris, France, with 106,566 employees and €41.1B annual revenue (FY2024).
Is this your business? Add your evidence →
Sanofi has delivered genuine absolute emission reductions (47% Scope 1&2, 10% Scope 3 vs 2019) and SBTi-validated net-zero targets to 2045. Weaknesses: Scope 3 progress lags operations; biodiversity gains are not yet net-positive; recurring pollution incidents at Mourenx plant; misaligned trade association memberships undermine climate credibility.
Sanofi scores 50/100 (Making progress) on SINK's independent climate assessment, scored from public data only. Fees pay for the review, never the result. Last verified May 2026.
That places Sanofi joint 149th of 847 companies scored, and joint 4th of 19 in Healthcare / Pharmaceuticals.
Where Sanofi sits among healthcare / pharmaceuticals peers.
Among the 19 major healthcare / pharmaceuticals brands we've scored, Sanofi is tied =4th of 19, with 2 others.
Its three lowest-scoring questions, and what the evidence didn't show.
Quantified net-positive nature outcomes not yet achieved.
Group-wide circularity performance metrics not comprehensively quantified.
Specific water pollution reduction targets absent.
A score changes when the evidence does. We use new published evidence at the next rescore. Evidence that isn't public can count through an evidence review.
Use this score in tenders
Send the link, or the one-page score sheet. It links back to this page and every source. Free.
Open the score sheet →Add your evidence, £99
Scored low because little is published? Send us your evidence. A person reviews it and your score reflects what you really do. Done within 5 working days.
Evidence review →Go tender-ready, £495 a year
A yearly rescore, a check of up to 25 key suppliers and a score badge for your website (coming soon).
Get in touch →Strongest on Carbon Footprint — Operations and Targets & Commitments (8/10, 8/10). Weakest on Nature & Biodiversity Impact and Resource Use & Waste (6/10, 6/10).
The 3 companies in the sector scoring nearest above Sanofi.
Smith & Nephew reports genuine 63% absolute emissions cuts (Scope 1+2) and 59% Scope 3 reductions since 2021, backed by third-party verification.
See the breakdown →AstraZeneca has cut operational emissions 77.5% since 2015 and locked in science-based net-zero targets, but absolute supply chain emissions are rising 18.6% from baseline.
See the breakdown →GSK has credible climate infrastructure: verified Scope 1&2 data, SBTi-validated net-zero to 2045, and sector-leading nature disclosures.
See the breakdown →The formula and all 14 sources.
Same ten questions for every company. No private weighting.
SINK = (0.3 × Base + 0.7 × Performance) × Scale14 sources used in this assessment. All publicly available. Each row shows which of the ten questions it informed.
If you believe a source has been misread or a newer version exists, submit a challenge.
Sanofi is a multinational pharmaceutical company headquartered in Paris, France, with 106,566 employees and €41.1B annual revenue (FY2024). It manufactures prescription drugs, vaccines, and specialty care products across oncology, immunology, and rare diseases, ranking among Europe's largest pharma players.
One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.
No spam. Unsubscribe in one click.
Checking a company?
Search free →Asked to prove you're sustainable?
Get your business scored, free →Been scored?
See what's behind your number →Fees pay for the review, never the result.